New luxury home community features elegant designs in a serene setting COLLEGEVILLE, Pa., March 09, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the grand opening of Linden Ridge, a boutique community of 26 single-family homes in Collegeville, Pennsylvania. The Sales Center and professionally designed model home, located at 12 Scholl Drive, is now open for home shoppers.Linden Ridge offers stunning two-story home designs ranging from approximately 2,776 to over 3,700 square feet, with 4 to 5 bedrooms, 2.5 to 5.5 bathrooms, and basements. Each home includes spacious, flexible living spaces and is situated on a private home site, many of which are located on a cul-de-sac. Homes in this exclusive community are priced from the mid-$900,000s. “Linden Ridge...

Investor News                                                    9 March 2026 How AI is affecting our industry – Q&A with CEO André Rogaczewski André Rogaczewski, CEO and Co-founder of Netcompany, will give his perspective on how AI is affecting the Tech industry and answer questions on the topic. For a brief introduction, please find a short video here: netcompany.com  The call is hosted by Bank of America. Event title:How AI is affecting our industry – Q&A with CEO André Rogaczewski Date and Time:11/03/2026 at 14:30 – 15:15 CET Register for the event here.Webinar Registration – Zoom Additional informationFor additional information, please contact: Netcompany Group A/SFrederikke Linde, Head of IR, +45 60 62 60 87AttachmentNews Netcompany – How AI is affecting our industry –...

ATHENS, Greece, March 09, 2026 (GLOBE NEWSWIRE) — Capital Clean Energy Carriers Corp. (the “Company”, “CCEC,” “we” or “us”) (NASDAQ: CCEC), an international owner of ocean-going vessels, today announces that Martin Houston has been appointed Chairman of the company with Keith Forman moving to a new role as Vice-Chairman. Martin Houston said: “I am immensely proud and privileged to take on the role of Chairman at Capital Clean Energy Carriers as we enter a dynamic period of growth, with the global LNG and LNG shipping markets projected to expand by 50% over next five years. Under Keith’s stewardship as Chairman, the company and its management have successfully navigated a repositioning, now focusing on gas transportation with a focus on LNG shipping. I am delighted that Keith will continue to play an active role in the company’s...

Today, 9 March 2026, KommuneKredit has published its Annual Report 2025. SummaryProfit before value adjustments and tax came to DKK 507 million, down by DKK 16 million on the year-earlier period, which is in line with our guidance in the interim report. Comprehensive income for the year amounted to DKK -44 million compared with DKK 8 million in 2024. Net interest income came to DKK 641 million for 2025, down by DKK 89 million on last year. The value of total loans and leases was up by DKK 6 billion to DKK 200 billion at end-2025. Common Equity Tier 1 (CET1) capital, which corresponds to equity, declined from 10,188 million at end-2024 to DKK 10,099 million.Since 1899, KommuneKredit has provided funding to municipalities and regions in Denmark through the issuance of bonds in the international capital markets. That funding model was...

HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical models of pancreatic cancer, lung cancer and ovarian cancer are presentedThe development of kRAS inhibitors for different types of solid tumors is currently an area of intense global activityMelbourne, Australia, March 09, 2026 (GLOBE NEWSWIRE) — Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that compelling data describing new clinical opportunities for its lead drug narmafotinib was presented at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics in Los Angeles, California on Friday March 6. The poster presentation discloses preclinical data demonstrating...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancers Mechanisms of action support enhanced activity of GSK-3β plus RAS inhibition Preclinical combination results expected in 2H2026CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the launch of an expanded research initiative evaluating combinations of its clinical-stage GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies. Despite recent advances in RAS-targeted therapies, adaptive...

TORONTO, March 09, 2026 (GLOBE NEWSWIRE) — Mink Ventures Corporation (TSXV:MINK) (“Mink” or the “Company“) today announced that it has completed a single, vertical drill hole (549 meters) at its Montcalm Ni Cu Co project, Timmins Ontario (Figure 1). Mink’s Montcalm project, located within the Montcalm Gabbro Complex, is adjacent to Glencore’s Montcalm Mine, with historical production of 3.93 million tonnes of ore grading 1.25% Ni, 0.67% Cu and 0.051% Co (Ontario Geological Survey, Atkinson, 2010). The objective of the drill program at Montcalm was to drill test a deep seated, high priority, 3D Borehole Induced Polarization (BHIP) target with coincident airborne VTEM, airborne gravity, and airborne magnetic high responses, located approximately 500 meters below surface (Figure 3). The BHIP target zone shown in Figure...

Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning. CHARLOTTE, N.C., March 09, 2026 (GLOBE NEWSWIRE) — Dentsply Sirona and Siemens Healthineers are pleased to share key findings from the clinical trial for validation of their dental-dedicated MRI system. In addition to confirming its significant potential...

Ceremony highlights Eagle’s recent public listing and Nasdaq debut under ticker “NUCL” RENO, Nev., March 09, 2026 (GLOBE NEWSWIRE) — Eagle Nuclear Energy Corp. (“Eagle” or the “Company”), a next-generation nuclear energy company which owns the largest conventional, measured and indicated uranium deposit in the United States, today announced that CEO Mark Mukhija will ring the Nasdaq Opening Bell at 9:30 a.m. ET on Wednesday, March 11, in recognition of the Company’s recent public listing. Eagle officially commenced trading on the Nasdaq on February 25, 2025, under the ticker symbols “NUCL”, marking a new chapter as a publicly traded U.S.-focused uranium development company. Eagle is the first domestic uranium resource exploration company with exclusive small modular reactor (SMR) technology to list on a U.S. exchange. Anchored...

March 9, 2026 Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life’s a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization’s vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life’s a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated exclusively to FAP, providing essential resources, community support, and awareness for patients and families facing this rare genetic...